Your browser is no longer supported. Please, upgrade your browser.
NEW! We've added Bitcoin charts to our Forex section. ×
Amgen Inc.
IndexS&P 500 P/E21.09 EPS (ttm)7.41 Insider Own0.10% Shs Outstand760.32M Perf Week-4.63%
Market Cap118.81B Forward P/E14.80 EPS next Y10.56 Insider Trans-9.82% Shs Float759.13M Perf Month-2.45%
Income5.71B PEG1.87 EPS next Q2.40 Inst Own82.70% Short Float1.21% Perf Quarter-0.44%
Sales20.58B P/S5.77 EPS this Y0.90% Inst Trans-0.28% Short Ratio2.79 Perf Half Y-2.70%
Book/sh34.83 P/B4.49 EPS next Y10.21% ROA8.20% Target Price182.06 Perf Year37.27%
Cash/sh35.67 P/C4.38 EPS next 5Y11.29% ROE22.40% 52W Range112.79 - 172.75 Perf YTD-0.90%
Dividend3.16 P/FCF20.47 EPS past 5Y8.20% ROI10.20% 52W High-9.54% Beta0.49
Dividend %2.02% Quick Ratio5.10 Sales past 5Y6.50% Gross Margin80.70% 52W Low38.54% ATR3.36
Employees17900 Current Ratio5.50 Sales Q/Q11.30% Oper. Margin37.00% RSI (14)39.93 Volatility1.76% 1.87%
OptionableYes Debt/Eq1.14 EPS Q/Q50.70% Profit Margin27.70% Rel Volume1.34 Prev Close157.35
ShortableYes LT Debt/Eq1.13 EarningsApr 21 AMC Payout34.90% Avg Volume3.30M Price156.26
Recom2.30 SMA20-2.64% SMA50-3.43% SMA2002.18% Volume4,413,107 Change-0.69%
May-28-15Reiterated Deutsche Bank Buy $200 → $192
Apr-22-15Reiterated UBS Buy $175 → $185
Apr-22-15Reiterated RBC Capital Mkts Outperform $178 → $185
Oct-29-14Reiterated Argus Buy $140 → $185
Oct-28-14Reiterated RBC Capital Mkts Outperform $150 → $165
Sep-08-14Reiterated RBC Capital Mkts Outperform $138 → $150
Aug-04-14Reiterated Argus Buy $135 → $140
Jul-30-14Reiterated RBC Capital Mkts Outperform $125 → $138
Jul-18-14Reiterated Deutsche Bank Buy $144 → $149
Apr-23-14Reiterated Oppenheimer Perform $121 → $122
Mar-21-14Reiterated Barclays Equal Weight $115 → $130
Jan-31-14Reiterated Argus Buy $130 → $135
Nov-20-13Reiterated Deutsche Bank Buy $138 → $142
Aug-29-13Reiterated UBS Buy $121 → $124
Aug-27-13Reiterated Barclays Overweight $105 → $115
Jul-31-13Reiterated Oppenheimer Perform $100 → $109
Apr-24-13Reiterated Deutsche Bank Buy $108 → $115
Apr-15-13Reiterated Barclays Equal Weight $90 → $105
Apr-08-13Reiterated RBC Capital Mkts Outperform $95 → $105
Jan-25-13Upgrade Argus Hold → Buy $96
May-29-15 02:18PM  Doctors hail new front in fight against cancer at Financial Times
01:43PM  Build a Billionaire Portfolio With These 20 Stocks at TheStreet
09:29AM  Amgen, Merck Expand Collaboration at The Wall Street Journal
08:30AM  Amgen And Merck Announce Expansion Of Collaboration To Support Studies Of Talimogene Laherparepvec In Combination With KEYTRUDA® (Pembrolizumab) In Patients With Head And Neck Cancer PR Newswire
06:45AM  Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease PR Newswire
May-28-15 04:00PM  Amgen Launches Program To Further Advance Basic Biology Research PR Newswire
03:48PM  Big Pharma and Insurers Play Nice at Bloomberg
10:03AM  ASCO Immunotherapy Preview: These Cancer-Killing Viruses May Save Lives at Forbes
May-27-15 07:36PM  PRIMECAP Sells Portions of Its Top Two Stakes
04:30PM  Amgen To Present At The Jefferies 2015 Global Healthcare Conference PR Newswire
04:00PM  Amgen To Advance Understanding Of The Treatment Of Blood Cancers At 20th Congress of European Hematology Association (EHA) PR Newswire
10:16AM  Here Is How AstraZeneca and Amgen Will Be Hit By The Cancelled Collaboration
May-26-15 08:56PM  Amgen, AstraZeneca End Development Pact; Shares Sink
07:14PM  Amgen Gets 1 Step Closer to Another Blockbuster at Investopedia
04:32PM  CNBC update: Skin cancer study
04:14PM  Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma PR Newswire
12:43PM  First Solar shine dims on downgrade at Financial Times
12:39PM  Amgen Down After Suicides Kill AstraZeneca Deal at Investor's Business Daily
12:30PM  Actavis to Continue Selling Namenda IR under Court Ruling - Analyst Blog
10:55AM  'Suicidal ideation' leads to end of Amgen-AstraZeneca drug partnership at
09:26AM  What Were Trading
09:11AM  Time Warner Cable soars on Charter deal; Etsy falls on Amazon threat; Apple promotion
09:06AM  Morning Movers: Charter Bid Lifts Time Warner Cable; AstraZeneca Slips as Amgen Bails on Drug Development at
08:05AM  Bulls' long holiday; Time Warner Cable's new deal; Amazon takes on Etsy
07:54AM  Early movers: TWC, AAPL, CTRP, CRM, GM & more at CNBC
06:58AM  AstraZenecas Prospects Weaken as Amgen Exits Drug Partnership at Bloomberg
04:31AM  AstraZeneca hit after psoriasis drug linked to suicide fears Reuters
01:48AM  Pharma Trumps All Healthcare Sectors In Executive Compensation at Forbes
01:00AM  Fight over hot new cholesterol drugs may be won in milligrams Reuters
May-25-15 01:55PM  AstraZeneca, Amgen End Psoriasis Drug Brodalumab Deal - Analyst Blog
09:10AM  Amgen's PCSK9 Inhibitor a Step Closer to EU Approval - Analyst Blog
May-23-15 09:30AM  The Most Loved Biotechs of Big Hedge Funds at 24/7 Wall St.
May-22-15 08:34PM  Amgen Ends Psoriasis-Drug Partnership With AstraZeneca at The Wall Street Journal
06:37PM  Amgen ends partnership with AstraZeneca on psoriasis drug
05:27PM  Amgen ends work on experimental psoriasis drug
04:44PM  Amgen ends collaboration with AstraZeneca on inflammation drug
04:29PM  Amgen Ends Drug Pact With AstraZeneca After Signs of Suicide at Bloomberg
04:22PM  Amgen to terminate participation in co-development and commercialization of brodalumab PR Newswire
02:45PM  A Beautiful Biotech Summer? at
07:31AM  Amgen Receives Positive CHMP Opinion For Use Of Repatha (Evolocumab) For The Treatment Of High Cholesterol PR Newswire
07:23AM  Amgen first to win EU backing for new kind of cholesterol drug Reuters
May-21-15 03:50PM  J&J (JNJ) to File for More than 10 New Products by 2019 - Analyst Blog
02:18PM  Why Do Biotech Stocks Look Attractive?
09:34AM  Billionaire Dan Loeb Slightly Shuffles Third Points Top Picks, Selling Off Large Alibaba Group Holding Ltd (BABA) Stake at Insider Monkey
May-20-15 04:07PM  The 25 best healthcare companies to work for in America Business Insider
02:50PM  Top 10 stocks of the David Letterman era
01:55PM  How biotechs are affecting J&J's business
May-19-15 12:04PM  Amgen cholesterol drug could get EU green light this week Reuters
08:33AM  3 Best Biotech Stocks to Add to Your Portfolio at TheStreet
May-18-15 04:00PM  Amgen Appoints Jonathan P. Graham Senior Vice President, General Counsel And Secretary PR Newswire
12:32PM  15 Years Later: A Look At The Nasdaq Composite Then and Now at Forbes
09:20AM  Kite Pharma Narrows Q1 Loss, Misses Estimates; Gives View - Analyst Blog
May-15-15 06:13PM  Health Care Sector Delivers Healthy Q1 Results at Investor's Business Daily
04:31PM  IPO Stock Watch: Alder Soars On Migraine Drug Results at Investor's Business Daily
04:30PM  Amgen Announces Positive Results on Migraine Candidate - Analyst Blog
01:13PM  It finally rains in California
06:06AM  AMGEN INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
04:00AM  Amgen Presents First Phase 2 Data For AMG 334 In The Prevention Of Episodic Migraine PR Newswire
May-14-15 05:58PM  Amgen Announces Voting Results of Annual Meeting of Stockholders PR Newswire
02:32PM  Cancer data deluge
02:07PM  Biotech: Asco Giveth, Asco Taketh Away at
11:42AM  DuPont win over Peltz is a win for investors at CNBC
May-13-15 05:00PM  Amgen Data At ASCO 2015 Highlight Oncology Pipeline And Portfolio PR Newswire
02:36PM  Biotech to watch ahead of ASCO
01:43PM  Global Yields and Debt Issues Hit Investment-Grade Bonds
10:06AM  Healthcare AM Winners and Losers: May 13, 2015
01:00AM  How DNA sequencing is transforming the hunt for new drugs Reuters
May-12-15 05:44PM  FDA panel approves Vertex drug
04:41PM  Ligand Pharmaceuticals Tops Q1 Earnings, Affirms View - Analyst Blog
04:06PM  Amgen's Breakaway From Cancer® Announces Winners Of Its Nationwide Search For Champions In The Fight Against Cancer PR Newswire
08:05AM  Short Sellers Start to Get Nervous on Biotech at 24/7 Wall St.
May-11-15 10:19PM  5 Things Amgen's Management Wants You to Know at Investopedia
04:05PM  Amgen To Present AMG 334 Data At 17th Congress of the International Headache Society PR Newswire
12:33PM  Business events scheduled for Tuesday
12:22PM  ETFs in Focus on Impressive Q1 Biotech Earnings - ETF News And Commentary
May-10-15 09:48PM  Defenders Unite Against Cyber Threats In Healthcare at Forbes
May-09-15 10:49AM  The Best And Worst ETFs Of The Week Amid Biotech Rebound
May-08-15 05:06PM  Oracle and Amgen Issues Drive High-Grade Primary Bond Market
03:25PM  Amgen wins injunction against Novartis' biosimilar drug at
08:45AM  Pharmalot.. Pharmalittle.. As the Weekend Nears: We're Catching up on Amgen, Sanofi and Much More!! at The Wall Street Journal
01:11AM  [$$] Business Watch: News Digest at The Wall Street Journal
May-07-15 08:12PM  Business Watch: News Digest at The Wall Street Journal
05:41PM  Novartis 'biosimilar' drug blocked by U.S. appeals court Reuters
04:20PM  Will Ligand Pharmaceuticals (LGND) Miss on Q1 Earnings? - Analyst Blog
02:41PM  Novartis AG's 'biosimilar' drug sale blocked by U.S. appeals court Reuters
01:50PM  Court Blocks Novartis Copy of Amgen Cancer-Care Drug at The Wall Street Journal
11:29AM  Regeneron expects Eylea sales to grow faster than expected
07:23AM  Regeneron profit rises as Eylea sales jump
May-06-15 09:32PM  Under pressure, FDA to hold public meeting on off-label use Reuters
08:46AM  Goldman Sachs Previews ASCO Cancer Conference With Amgen, Celgene And Clovis Oncology
May-05-15 04:42PM  Corporate Debt Issues and FOMC Statement Weigh on Bond Yields
02:43PM  Amgen Indulges in Another Rheumatoid Arthritis Drug Price Increase at TheStreet
12:46PM  Healthcare AM Winners and Losers: May 04, 2015
12:46PM  Healthcare Winners and Losers: May 04, 2015
10:48AM  FOMC Statement, Risk-On Sentiment Push Treasury Yields Higher
10:30AM  Pfizer, other drug giants to drive biotech
10:10AM  Stock Market News for May 05, 2015 - Market News
09:48AM  Beyond Pharma: 3 Healthcare Choices - Analyst Blog
May-04-15 05:04PM  Amgen To Present At The Deutsche Bank 40th Annual Healthcare Conference at noodls
04:17PM  Amgen To Present At The Deutsche Bank 40th Annual Healthcare Conference PR Newswire
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company's principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. Its principal products also comprise EPOGEN for the treatment of dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis. The company's other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with AstraZeneca Plc; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. The company was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Balachandran MadhavanEVP, OperationsMay 07Option Exercise55.7221,7501,211,94855,144May 11 04:56 PM
Balachandran MadhavanEVP, OperationsMay 07Sale157.8721,7503,433,69533,394May 11 04:56 PM
Tross Stuart ASVP, Human ResourcesApr 23Sale169.313,012509,96421,923Apr 24 04:53 PM
Harper Sean EEVP, Research & DevelopmentApr 22Sale171.5828,0004,804,24047,920Apr 23 05:04 PM
Tross Stuart ASVP, Human ResourcesMar 03Sale157.744,415696,42720,237Mar 04 08:25 PM
BALTIMORE DAVIDDirectorMar 02Sale158.763,647579,01131,159Mar 03 08:55 PM
BALTIMORE DAVIDDirectorFeb 19Option Exercise42.135,000210,65036,159Feb 23 04:13 PM
Bradway Robert AChairman, CEO and PresidentFeb 11Option Exercise42.1384,0003,538,920258,641Feb 12 09:09 PM
Bradway Robert AChairman, CEO and PresidentFeb 11Sale152.6922,0003,359,116218,102Feb 12 09:09 PM
COFFMAN VANCE DDirectorFeb 06Option Exercise42.135,000210,65038,460Feb 06 06:23 PM
HERRINGER FRANK CDirectorFeb 05Option Exercise42.135,000210,65025,449Feb 05 08:11 PM
HERRINGER FRANK CDirectorFeb 05Buy152.293,000456,8702,000Feb 05 08:11 PM
de Carbonnel FrancoisDirectorDec 03Sale168.013,000504,04119,159Dec 03 05:00 PM
COFFMAN VANCE DDirectorSep 05Option Exercise56.7920,0001,135,80041,623Sep 09 06:54 PM
Harper Sean EEVP, Research & DevelopmentAug 05Sale127.2914,0001,782,12659,503Aug 07 04:22 PM